Abstract

Monoamine oxidase inhibitors (MAOIs) have attracted controversy ever since they were introduced to psychiatry 30 years ago. Concern about hypertensive crises and doubts about their efficacy compared with the tricyclic antidepressives, contributed to this lack of consensus. More up-to-date studies allow a reassessment of their efficacy, and two recent editorials highlight their value.^1,2